These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15717359)

  • 1. Top stories of 2004. Bad nukes comes in threes.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):1. PubMed ID: 15717359
    [No Abstract]   [Full Text] [Related]  

  • 2. Top stories of 2004. To 3TC or not to 3TC?
    Albrecht H
    AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717368
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA notifications. Gilead issues letter about virologic failure.
    AIDS Alert; 2003 Dec; 18(12):159-60. PubMed ID: 14696542
    [No Abstract]   [Full Text] [Related]  

  • 5. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 6. Top stories of 2008. Antiretroviral rollout--successes and challenges.
    Friedland GH
    AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detectable viral loads and slow development of resistance.
    Gadd C
    IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
    [No Abstract]   [Full Text] [Related]  

  • 8. Top stories of 2004. Resistance rates: high in new infections, higher in treated ones.
    Zuger A
    AIDS Clin Care; 2005 Jan; 17(1):3. PubMed ID: 15717363
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Five-year results from an NNRTI-based regimen.
    TreatmentUpdate; 2005; 17(1):6. PubMed ID: 17225317
    [No Abstract]   [Full Text] [Related]  

  • 10. Top stories of 2004. Perinatal transmission interventions: the benefits come with resistance.
    Coovadia H
    AIDS Clin Care; 2005 Jan; 17(1):2. PubMed ID: 15717360
    [No Abstract]   [Full Text] [Related]  

  • 11. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV integrase inhibitors show potent activity in clinical trials.
    Winslow DL
    AIDS Alert; 2007 Jan; 22(1):10-1. PubMed ID: 17722343
    [No Abstract]   [Full Text] [Related]  

  • 15. New studies highlight HIV-resistance trends. NNRTIs show upward trend.
    AIDS Alert; 2005 Jan; 20(1):5-6. PubMed ID: 15717353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of viral fitness.
    Geretti AM
    J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase.
    TreatmentUpdate; 2004; 16(3):8-9. PubMed ID: 17219608
    [No Abstract]   [Full Text] [Related]  

  • 18. Researcher presents vexing information on rilpivirine.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):10-2. PubMed ID: 19048650
    [No Abstract]   [Full Text] [Related]  

  • 19. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.